"We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets. Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy. In the Annual Report, we have outlined how this growth will fuel our strategy to become global leaders in rare diseases, building on our capabilities and strengths within the field", says Guido Oelkers, CEO.
Because we care, we need to act
Annual General Meeting 2018
The Annual General Meeting was held on Wednesday, May 9, 2018 at 15:00 at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.
